Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.